Investigational Drug Details
| Drug ID: | D612 |
| Drug Name: | Rapamycin |
| Synonyms: | AY 22989; CYPHER; CYPHER SELECT PLus; HYFTOR; NEVO; NPC-12; NPC-12G; NPC-12T; NSC 226080; NSC 606698; Rapalimus; Rapamune; Sirolimus |
| Type: | Miscellany |
| DrugBank ID: | -- |
| DrugBank Description: | -- |
| PubChem ID: | -- |
| CasNo: | -- |
| Repositioning for NAFLD: | No |
| SMILES: | -- |
| InChiKey: | -- |
| Molecular Weight: | -- |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | Immunosuppressants; Methylmalonyl CoA mutase stimulants; MTOR protein inhibitors; T lymphocyte inhibitors |
| Therapeutic Category: | -- |
| Clinical Trial Progress: | -- |
| Latest Progress: | Under investigation |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00006 | 35256934 | Acta Pharm Sin B | Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma. | Details |
| A00056 | 35240344 | Cell Mol Gastroenterol Hepatol | Activation of Liver mTORC1 Protects Against NASH via Dual Regulation of VLDL-TAG Secretion and De Novo Lipogenesis. | Details |
| A00093 | 35222075 | Front Physiol | MicroRNA-122-5p Inhibition Improves Inflammation and Oxidative Stress Damage in Dietary-Induced Non-alcoholic Fatty Liver Disease Through Targeting FOXO3. | Details |
| A00101 | 35219732 | Eur J Pharmacol | mTOR as an eligible molecular target for possible pharmacological treatment of nonalcoholic steatohepatitis. | Details |
| A00324 | 35134508 | J Nutr Biochem | Mechanisms of autophagic responses to altered nutritional status. | Details |
| A00342 | 35127372 | Acta Pharm Sin B | The cGAS-STING signaling in cardiovascular and metabolic diseases: Future novel target option for pharmacotherapy. | Details |
| A00343 | 35127371 | Acta Pharm Sin B | Therapeutic regulation of autophagy in hepatic metabolism. | Details |
| A00413 | 35093393 | Biochem Pharmacol | Targeting lipophagy as a potential therapeutic strategy for nonalcoholic fatty liver disease. | Details |
| A01179 | 34838715 | Mol Metab | A novel role of CRTC2 in promoting nonalcoholic fatty liver disease. | Details |
| A01279 | 34803916 | Front Endocrinol (Lausanne) | Sestrin2 as a Potential Target for Regulating Metabolic-Related Diseases. | Details |
| A01393 | 34762761 | FASEB J | Intracellular C3 prevents hepatic steatosis by promoting autophagy and very-low-density lipoprotein secretion. | Details |
| A01406 | 34758326 | Cell Rep | m6A mRNA methylation-directed myeloid cell activation controls progression of NAFLD and obesity. | Details |
| A01479 | 34732369 | Pharmacol Res | Ajugol enhances TFEB-mediated lysosome biogenesis and lipophagy to alleviate non-alcoholic fatty liver disease. | Details |
| A01585 | 34684653 | Nutrients | Coffeeberry Activates the CaMKII/CREB/BDNF Pathway, Normalizes Autophagy and Apoptosis Signaling in Nonalcoholic Fatty Liver Rodent Model. | Details |
| A01932 | 34558854 | Hepatol Commun | RORα Enhances Lysosomal Acidification and Autophagic Flux in the Hepatocytes. | Details |
| A02352 | 34406209 | Braz J Med Biol Res | α,β-Amyrin prevents steatosis and insulin resistance in a high-fat diet-induced mouse model of NAFLD via the AMPK-mTORC1-SREBP1 signaling mechanism. | Details |
| A02413 | 34382907 | Autophagy | Lipotoxicity-induced STING1 activation stimulates MTORC1 and restricts hepatic lipophagy. | Details |
| A02415 | 34381984 | JHEP Rep | The role of cGAS-STING signalling in liver diseases. | Details |
| A02520 | 34342231 | J Agric Food Chem | Phloridzin Ameliorates Lipid Deposition in High-Fat-Diet-Fed Mice with Nonalcoholic Fatty Liver Disease via Inhibiting the mTORC1/SREBP-1c Pathway. | Details |
| A02603 | 34312684 | J Mol Med (Berl) | Lipid metabolism, inflammation, and foam cell formation in health and metabolic disorders: targeting mTORC1. | Details |